XTX Topco Ltd Buys New Shares in Embecta Corp. (NASDAQ:EMBC)

XTX Topco Ltd purchased a new position in Embecta Corp. (NASDAQ:EMBC) in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 30,511 shares of the company’s stock, valued at approximately $630,000. XTX Topco Ltd owned about 0.05% of Embecta as of its most recent SEC filing.

Several other institutional investors have also added to or reduced their stakes in the business. Jane Street Group LLC lifted its stake in shares of Embecta by 156.1% in the 3rd quarter. Jane Street Group LLC now owns 176,487 shares of the company’s stock valued at $2,488,000 after acquiring an additional 107,567 shares during the last quarter. Barclays PLC increased its stake in Embecta by 41.1% in the 3rd quarter. Barclays PLC now owns 97,930 shares of the company’s stock worth $1,381,000 after purchasing an additional 28,523 shares during the period. Geode Capital Management LLC boosted its stake in shares of Embecta by 3.4% during the third quarter. Geode Capital Management LLC now owns 1,387,273 shares of the company’s stock valued at $19,564,000 after purchasing an additional 45,228 shares during the period. Wilmington Savings Fund Society FSB bought a new position in shares of Embecta in the third quarter worth approximately $217,000. Finally, Garden State Investment Advisory Services LLC purchased a new position in shares of Embecta in the third quarter worth $438,000. 93.83% of the stock is currently owned by hedge funds and other institutional investors.

Embecta Stock Performance

NASDAQ EMBC opened at $11.34 on Friday. The stock has a market cap of $659.24 million, a P/E ratio of 11.34, a price-to-earnings-growth ratio of 0.78 and a beta of 1.23. Embecta Corp. has a fifty-two week low of $10.00 and a fifty-two week high of $21.48. The stock has a 50 day simple moving average of $13.12 and a two-hundred day simple moving average of $15.88.

Embecta (NASDAQ:EMBC) last announced its quarterly earnings results on Thursday, February 6th. The company reported $0.65 EPS for the quarter, topping analysts’ consensus estimates of $0.45 by $0.20. Embecta had a negative return on equity of 19.22% and a net margin of 5.25%. Sell-side analysts predict that Embecta Corp. will post 2.85 earnings per share for the current year.

Embecta Dividend Announcement

The business also recently declared a quarterly dividend, which was paid on Friday, March 14th. Investors of record on Friday, February 28th were given a dividend of $0.15 per share. This represents a $0.60 annualized dividend and a dividend yield of 5.29%. The ex-dividend date of this dividend was Friday, February 28th. Embecta’s dividend payout ratio is currently 60.00%.

Insider Buying and Selling

In other Embecta news, Director Milton Mayo Morris sold 3,100 shares of the company’s stock in a transaction that occurred on Thursday, February 13th. The stock was sold at an average price of $16.38, for a total transaction of $50,778.00. Following the transaction, the director now owns 36,133 shares in the company, valued at approximately $591,858.54. This represents a 7.90 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. 0.42% of the stock is owned by insiders.

Analysts Set New Price Targets

Separately, Mizuho assumed coverage on shares of Embecta in a research report on Thursday, April 10th. They set a “neutral” rating and a $15.00 price target for the company.

Embecta Company Profile

Embecta Corp., a medical device company, focuses on the provision of various solutions to enhance the health and wellbeing of people living with diabetes. Its products include pen needles, syringes, and safety injection devices, as well as digital applications to assist people with managing patient's diabetes.